BioSpace News Archive

Drug Development

ReCode, Vertex and 4DMT Seek to Help Untreated Cystic Fibrosis Patients

Drugs that act on the CFTR protein only work in patients who produce the protein in the first place. That leaves 6% of patients hanging.

June 1, 2023
·
7 min read
·
Ashley P. Taylor
Policy

FDA Warns About Compounded Versions of Novo Nordisk’s Ozempic, Wegovy

The regulator says drug compounders are selling products that falsely claim to contain the same active ingredient, semaglutide, as the blockbuster diabetes and obesity drugs.

June 1, 2023
·
2 min read
·
Nick Paul Taylor
Job Trends

Three New Developments Bring New Jobs, Opportunity

Despite oft-reported news of layoffs, the life sciences industry continues to have golden spots of expansions in terms of jobs, year-on-year revenue and in building new facilities and programs.

June 1, 2023
·
2 min read
·
Lisa Munger
Deals

Eikon Acquires Broad Development Pipeline, Raises $106M in Series C Funding

Roger Perlmutter’s company announced the addition Thursday of myriad early- to mid-stage assets in the cancer and neurodegenerative disease spaces.

June 1, 2023
·
2 min read
·
Heather McKenzie
FDA

FDA Approves Pfizer’s RSV Vaccine for Older Adults

Abrysvo’s approval in adults aged 60 years and above comes ahead of an expected August decision in the pediatric setting.

June 1, 2023
·
2 min read
·
Tristan Manalac
FDA

AstraZeneca Wins FDA Nod in Prostate Cancer, Trims IBD Pipeline

The company added an indication to Lynparza’s label for the treatment of adults with metastatic castration-resistant prostate cancer, while cutting an antibody for Crohn’s disease and ulcerative colitis.

June 1, 2023
·
2 min read
·
Tristan Manalac
Job Trends

MassBio Launches Nonprofit to Fill Hiring and Diversity Gaps in Massachusetts

Bioversity plans address two key pain points in the industry: the current system cannot produce enough talent to keep up with demand, and the workforce as a whole lacks diversity.

June 1, 2023
·
3 min read
·
Rosemary Scott
Policy

FDA Action Alert: Merck, Sanofi/AstraZeneca and Eisai/Biogen

The FDA has three high-profile events this week, including one target action date and two advisory committee meetings—one to discuss potential traditional approval for Alzheimer’s drug Leqembi.

June 1, 2023
·
3 min read
·
Tristan Manalac
Genetown

Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

Oculis Holding AG announced the pricing of a follow-on public offering of 3,500,000 ordinary shares at a public offering price of $11.50 per ordinary share, for gross proceeds of $40.25 million, before deducting underwriting discounts and commissions and offering expenses.

June 1, 2023
·
4 min read
Job Trends

Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan

Sanofi launches Action 2023, its global employee shareholder plan, open to around 86,000 employees in 56 countries.

June 1, 2023
·
5 min read